pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 3, 2007, Pages 274-279

  Ramanathan, Srinivasan ^a   Shen, Gong ^a   Cheng, Andrew ^a   Kearney, Brian P ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug interaction; Emtricitabine; GS 9137; Integrase; Pharmacokinetics; Tenofovir

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GS 9137; GS 9137 PLUS RITONAVIR; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; FEMALE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; THORAX PAIN; VOMITING;

ADENINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; QUINOLONES; RITONAVIR;

EID: 34347347164     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d88c     Document Type: Article

References (21)

1. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSInfo Web site. Available at: http://AIDSinfo.nih.gov. Accessed October 10, 2006.
2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Role of HIV drug resistance testing in antiretroviral drug development. November 2004. Available at: http://www.fda.gov/cder/guidance/5879dft.html. Accessed December 11, 2006.
3. del Rio C. Current concepts in antiretroviral therapy failure. Top HIV Med. 2006;14:102-106.
4. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1-5.
5. Munoz de Benito RM, Arribas Lopez JR. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Expert Rev Anti Infect Ther. 2006;4:523-535.
6. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.
7. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on co-administration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278-283.
8. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations (revision 1). March 2003. Available at: http://www.fda.gov/cder/guidance/5356fnl.html. Accessed December 11, 2006.
9. Gilead Sciences. Truvada (US prescribing information). Foster City, CA: Gilead Sciences; 2006.
10. Boffito M, Pozniak A, Kearney BP, et al. Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. Antimicrob Agents Chemother. 2005;49:4386-4389.
11. Kearney BP, Flaherty J, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects. Presented at: Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; 2001; Athens.
12. Zong J, Blum MR, Chittick G, et al. A steady-state evaluation of the potential pharmacokinetic interaction between emtricitabine and zidovudine in healthy volunteers. Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago.
13. Smith PF, Kearney BP, Liaw S, et al. Effect of tenofovir disoproxil fumarate on pharmacokinetics and pharmacodynamics of total R-, and S-methadone. Pharmacotherapy. 2004;24:970-977.
14. Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF and norgestimate/ethinyl estradiol: lack of a pharmacokinetic drug interaction. Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago.
15. Chittick GE, Zong J, Blum RM, et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob Agents Chemother. 2006;50:1304-1310.
16. Ray AS, Vela JE, Robinson KL, et al. Efflux of tenofovir by the multidrug resistance-associated protein 4 (MRP4) is not affected by HIV protease inhibitors. Presented at: 10th European AIDS Conference (EACS); 2005; Dublin.
17. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active tubular secretion of tenofovir and potential for a renal drug-drug interaction with HIV protease inhibitors. Presented at: Seventh International Workshop on Clinical Pharmacology of HIV Therapy; 2006; Lisbon.
18. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago.
19. Kearney BP, Ramanathan S, Cheng AK, et al. Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. J Clin Pharmacol. 2005;45:935-940.
20. Wang LH, Delehanty J, Blum MR, et al. FTC (emtricitabine): a potent and selective anti-HIV and anti-HBV agent demonstrating desirable pharmacokinetic characteristics. Presented at: 36th Annual Meeting of the Infectious Disease Society of America; 1998; Denver, CO.
21. Altice F, Mostashari F, Friedland GH. Trust and the acceptance of and the adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28:47-58.